Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Liabilities and Shareholders Equity (2020 - 2026)

Edgewise Therapeutics has reported Liabilities and Shareholders Equity over the past 7 years, most recently at $518.5 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $518.5 million for Q1 2026, up 14.11% from a year ago — trailing twelve months through Mar 2026 was $2.3 billion (up 14.3% YoY), and the annual figure for FY2025 was $552.6 million, up 13.51%.
  • Liabilities and Shareholders Equity reached $518.5 million in Q1 2026 per EWTX's latest filing, down from $552.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $613.3 million in Q2 2025 and bottomed at $257.4 million in Q2 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $454.4 million (2025), compared with a mean of $435.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 64.21% in 2024 before it decreased 17.95% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $367.1 million in 2022, then fell by 7.37% to $340.0 million in 2023, then skyrocketed by 43.17% to $486.8 million in 2024, then increased by 13.51% to $552.6 million in 2025, then fell by 6.17% to $518.5 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for EWTX at $518.5 million in Q1 2026, $552.6 million in Q4 2025, and $583.5 million in Q3 2025.